Welcome to our dedicated page for Theratechnologies Common news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies Common stock.
Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.
Core Products:
- EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
- Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.
Pipeline Products:
- F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
- TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
- TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.
Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.
News
Rhea-AI Summary
Theratechnologies Inc. reported Q1 2024 revenue of $16.2 million, marking the third consecutive quarter of near-flat-to-positive Adjusted EBITDA. FY2024 revenue guidance is confirmed between $87-$90 million with Adjusted EBITDA of $13-15 million. The Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer is accelerating. Recent business highlights include the completion of enrollment for Phase 1 trial participants and the appointment of new Board members. Financially, there was an 18.4% decrease in revenue compared to the previous year, with EGRIFTA SV® and Trogarzo® sales declining. Despite lower revenues, the net loss improved to $4.4 million from $10.4 million in Q1 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.9%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. presented preclinical data at the AACR annual meeting highlighting the significant tumor regression in colorectal cancer and triple-negative breast cancer xenograft models using investigational camptothecin-peptide conjugates. The study also showed synergistic anti-tumor efficacy with combination therapy. The SORT1+ Technology™ platform utilizes a novel peptide to target SORT1 for receptor-mediated internalization of anticancer agents. The platform demonstrated promising tolerability and anti-tumor effects, supporting its potential in developing novel peptide-drug conjugates for various cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. appoints Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and Audit Committee. Ms. Tea's extensive financial and business development experience brings valuable insights to the Company as it focuses on commercial business and new partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
Rhea-AI Summary
Theratechnologies Inc. will report financial results and provide a business update for its first quarter on April 10, 2024. The call will be hosted by CEO Paul Lévesque and other key members of the management team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. announces the presentation of two posters at the AACR Annual Meeting 2024, showcasing the potential of their SORT1+ Technology™ platform for treating colorectal cancers. The studies demonstrate the effectiveness of sudocetaxel zendusortide (TH1902) in activating anti-PD-L1 immunotherapy tumor cell killing and introduce new camptothecin-peptide conjugates for SORT1+ colorectal cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.7%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. announced a shift towards a commercial focus by phasing down preclinical oncology research activities to prioritize the Phase 1 clinical trial of sudocetaxel zendusortide. The company aims to attract an oncology R&D partner leveraging its SORT1+ Technology platform. Theratechnologies also shared preclinical data at the AACR annual meeting and initiated the next cohort of patients in the Phase 1 trial. The restructuring will incur cash and non-cash charges to optimize the organizational cost structure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
Rhea-AI Summary
Theratechnologies Inc. appoints Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and Audit Committee. Mr. Zwick brings extensive experience in the biotech and pharmaceutical industry, global finance, and corporate strategy to guide Theratechnologies towards profitability and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. announces progression to next dose level in Phase 1 clinical trial for sudocetaxel zendusortide in advanced ovarian cancer patients, with positive safety outcomes and enrollment of first patient in second cohort.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
-
Rhea-AI Summary
Theratechnologies Inc. announces the resignation of Mr. Alain Trudeau from the Board of Directors and the Audit Committee. The Company plans to appoint a new independent director to ensure compliance with securities regulation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
Rhea-AI Summary
Theratechnologies receives a refusal to file letter from the FDA for Trogarzo® IM administration, impacting their supplemental Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
FAQ
What is the current stock price of Theratechnologies Common (THTX)?
The current stock price of Theratechnologies Common (THTX) is $1.8262 as of December 24, 2024.
What is the market cap of Theratechnologies Common (THTX)?
The market cap of Theratechnologies Common (THTX) is approximately 84.0M.
What does Theratechnologies Inc. specialize in?
Theratechnologies Inc. specializes in biopharmaceutical solutions for HIV and serious medical conditions like cancer.
Where are Theratechnologies' products marketed?
Theratechnologies markets its products in the United States, Europe, and Canada.
What are the main products offered by Theratechnologies?
The main products include EGRIFTA and EGRIFTA SV for HIV-related lipodystrophy and Trogarzo for multidrug-resistant HIV-1.
What are Theratechnologies' pipeline products?
Pipeline products include the F8 formulation for HIV-associated lipodystrophy, TH-1902 for triple-negative breast cancer, and TH-1904 for ovarian cancer.
When was Theratechnologies Inc. founded?
Theratechnologies Inc. was founded in 1993.
Where is Theratechnologies Inc. headquartered?
Theratechnologies Inc. is headquartered in Montreal, Canada.
Who is a major customer of Theratechnologies?
RxCrossroads, based in the United States, is a major customer of Theratechnologies.
What is the significance of Trogarzo?
Trogarzo is an important treatment for patients with multidrug-resistant HIV-1, providing a crucial option for those with limited alternatives.
How does EGRIFTA benefit HIV patients?
EGRIFTA helps reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their health and quality of life.
What is Theratechnologies' approach to innovation?
Theratechnologies focuses on research and development to create innovative treatments for serious medical conditions and improve patient outcomes.
Theratechnologies Inc. Common